Home › Funds › Ikarian Capital, LLC › DMRA
Ikarian Capital, LLC position in DMRA
DAMORA THERAPEUTICS INC COM SHS · Health Care
Ikarian Capital, LLC reported holding 335,710 shares of DMRA (DAMORA THERAPEUTICS INC COM SHS) in its Q2 2026 13F filing — a position valued at US$8.7M, representing 1.40% of its reported portfolio and ranking #20 among its reported holdings. Ikarian Capital, LLC has disclosed DMRA holdings in 3 of the last 3 reported quarters, going back to Q4 2025.
Last updated: 2026-10-24 · Source: SEC EDGAR Form 13F-HR
How Ikarian Capital, LLC's DMRA position evolved
Ikarian Capital, LLC first disclosed a stake in DMRA in Q4 2025 at 285,710 shares (US$6.6M). The position peaked in Q2 2026 at 335,710 shares, worth US$8.7M. Across 3 filings, Ikarian Capital, LLC increased the stake 1 time(s), trimmed it 0 time(s) and left it unchanged 1 time(s). The most recent filing (Q2 2026) shows 335,710 shares valued at US$8.7M.
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q4 2025 | 285.71K | $6.57M | New |
| Q1 2026 | 335.71K | $8.69M | Add |
| Q2 2026 | 335.71K | $8.73M | Hold |
Dots on the line are colored by change type; missing quarters mean no position was reported.
About DMRA and 13F data
DMRA (DAMORA THERAPEUTICS INC COM SHS) is a Health Care company. 105 other funds we track also report a position in DMRA — the largest reported positions include Fairmount Funds Management LLC (US$226.6M), Avoro Capital Advisors LLC (US$98.4M), Venrock Adviser, LLC (US$93.7M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
Other funds holding DMRA
- Fairmount Funds Management LLC 8.71M sh · $226.63M · Q2 2026
- Avoro Capital Advisors LLC 3.78M sh · $98.40M · Q2 2026
- Venrock Adviser, LLC 3.60M sh · $93.73M · Q2 2026
- FCPM III SERVICES B.V. 2.44M sh · $63.49M · Q2 2026
- RA CAPITAL MANAGEMENT, L.P. 2.40M sh · $62.42M · Q2 2026
- Remedium Capital Partners, LLC 2.05M sh · $53.20M · Q2 2026
- Commodore Capital LP 1.94M sh · $50.43M · Q2 2026
- BRAIDWELL LP 1.62M sh · $42.15M · Q2 2026
- Bellevue Group AG 1.62M sh · $42.11M · Q2 2026
- a16z Capital Management, L.L.C. 1.24M sh · $32.15M · Q2 2026
- PERCEPTIVE ADVISORS LLC 1.22M sh · $31.81M · Q2 2026
- Cormorant Asset Management, LP 1.00M sh · $26.01M · Q2 2026
More on Ikarian Capital, LLC
FAQ
How long has Ikarian Capital, LLC held DMRA?
Ikarian Capital, LLC has disclosed DMRA holdings in 3 of the last 3 reported quarters, going back to Q4 2025.
What is Ikarian Capital, LLC's current position in DMRA?
As of Q2 2026, Ikarian Capital, LLC holds 335.71K shares of DMRA (DAMORA THERAPEUTICS INC COM SHS), valued at $8.73M, representing 1.40% of its reported portfolio and ranking #20.
Has Ikarian Capital, LLC been buying or selling DMRA?
In the latest 13F filing (Q2 2026), Ikarian Capital, LLC held unchanged its position in DMRA. The position peaked in Q2 2026 at 335.71K shares.
Which other funds hold DMRA?
Other major institutional holders of DMRA include Fairmount Funds Management LLC, Avoro Capital Advisors LLC, Venrock Adviser, LLC, among 105 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.